PS
JBIO

Principal Securities’s Jade Biosciences JBIO Stock Holding History

Principal Securities’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$43 – 1521
2025
Q3 		$43 Sell
5
-8
-62% -$65 ﹤0.01% 3722
2025
Q2 		$130 Buy
+13
New +$442 ﹤0.01% 3630

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Principal Securities's JBIO Position: Q4 2025 in Review

Principal Securities sold out of Jade Biosciences (JBIO) in Q4 2025, closing a stake of 5 shares — an estimated $43 sold.

Principal Securities first reported a position in JBIO in Q2 2025 and held it in 2 quarters. The position peaked at $130 in Q2 2025. 105 funds tracked by Wall St. Rank hold JBIO as of Q4 2025.

  • Principal Securities reported no remaining Jade Biosciences position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 5 Jade Biosciences shares in Q4 2025, an estimated $43.
  • Principal Securities first reported a position in Jade Biosciences in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Jade Biosciences position peaked at $130 in Q2 2025.
  • 105 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.